Registration Dossier

Toxicological information

Immunotoxicity

Currently viewing:

Administrative data

Description of key information

Key value for chemical safety assessment

Effect on immunotoxicity: via oral route

Endpoint conclusion
Endpoint conclusion:
no study available

Effect on immunotoxicity: via inhalation route

Endpoint conclusion
Endpoint conclusion:
no study available

Effect on immunotoxicity: via dermal route

Endpoint conclusion
Endpoint conclusion:
no study available

Additional information

There are no studies conducted with validated methods to assess whether there is an association between Bisphenol A exposure and immunotoxicity.

EFSA Opinion 2015 Conclusions on immune effects:

"Based on recent human studies, there are indications that Bisphenol A may be linked to immunological outcomes in humans, although these studies had limitations and confounding factors may have been present. A causal link between Bisphenol A exposure during pregnancy or in childhood and immune effects in humans cannot be established.

Studies in animals lend support to the possibility of immunological effects of Bisphenol A. Most of these studies suffered from shortcomings in experimental design and reporting. Although dose-responses could not be confidently established in most studies, a dose-related effect was observed in allergic lung inflammation.

Using a WoE approach, the CEF Panel assigned a likelihood level of “-as likely as not- to likely” to immunotoxic effects of Bisphenol A. Since the likelihood level for this endpoint is less than “likely” (see Appendix A), this endpoint was not taken forward for assessing the toxicological reference point, but was taken into account in the evaluation of uncertainty for hazard characterisation and risk characterisation."

Justification for classification or non-classification

Bisphenol A is included in Annex VI of Regulation (EC) No 1272/2008.